A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of the Fix-dose Combination Therapy With Gemigliptin 50mg and Rosuvastatin 20mg With Type 2 Diabetes and Dyslipidemia

NCT02126358 Phase 3 COMPLETED

To evaluate the efficacy and safety of the fix-dose combination therapy with Gemigliptin 50mg and Rosuvastatin 20mg with type 2 diabetes and dyslipidemia

Details

Lead sponsor	LG Life Sciences
Phase	Phase 3
Status	COMPLETED
Enrolment	290
Start date	2014-05
Completion	2016-03

Conditions

• Type 2 Diabetes
• Dyslipidemia

Interventions

• Gemigliptin and/or Rosuvastatin

Primary outcomes

• HbA1c change — Baseline(Day 0) to Treatment (last visit, w24)
• LDL-C change rate — Baseline(Day 0) to Treatment (last visit, w24)

Countries

South Korea